IP Library Patent Application 16189269
Patent Application
App. No. 16/189,269

Antibiotic Kit and Composition and Uses Thereof

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/189,269
Abstract

The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water, and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Claims (53)

1 - 91 . (canceled)

92 . A composition comprising:

(a) a foamable composition comprising:

i. a therapeutically effective amount of azelaic acid;

ii. a capric/caprylic triglyceride;

iii. surface-active agents;

iv. about 0.01% to about 5% by weight of the foamable composition of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent;

v. less than 5% by weight of the foamble composition of short chain alcohols having up to 5 carbon atoms; and

vi. water; and

(b) a propellant wherein the propellant comprises a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the composition,

wherein the surface active agents comprise a combination of at least one surfactant having a hydrophilic lipophilic balance of less than 9 and at least one surfactant having a hydrophilic lipophilic balance of equal to or more than 9.

93 . The composition of claim 92 , wherein the foamable composition is an oil-in-water emulsion.

94 . The composition of claim 92 , wherein the capric/caprylic triglyceride comprises about 2% to about 50% by weight of the foamable composition.

95 . The composition of claim 93 , wherein the surface active agent comprises between about 0.1% and about 5% by weight of the foamable composition.

96 . The composition of claim 92 ,

wherein said composition forms a thermally stable breakable foam upon release from an aerosol container.

97 . The composition of claim 96 ,

wherein the thermally stable foam collapses upon application of mechanical force.

98 . The composition of claim 92 , wherein the foamable composition contains less than 2% by weight of the composition of short chain alcohols.

99 . The composition of claim 92 , wherein upon release, foam is produced having a density range selected from (1) between about 0.01 gr/mL and about 0.1 gr/mL; and (2) between about 0.02 gr/mL and about 0.1 gr/mL.

100 . The composition of claim 92 , further comprising a therapeutically active foam adjuvant selected from the group consisting of fatty alcohols having 15 or more carbons in their carbon chain; fatty acids having 16 or more carbons in their carbon chain; fatty alcohols derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain; fatty alcohols having at least one double bond; fatty acids having at least one double bond; branched fatty alcohols; branched fatty acids; fatty acids substituted with a hydroxyl group; cetyl alcohol; stearyl alcohol; arachidyl alcohol; behenyl alcohol; 1-triacontanol; hexadecanoic acid; stearic acid; arachidic acid; behenic acid; octacosanoic acid; 12-hydroxy stearic acid, and mixtures thereof.

101 . The composition of claim 100 , wherein the foam adjuvant comprises about 0.1% to about 5% by weight of the foamable composition.

102 . The composition of claim 92 , further comprising a therapeutically active foam adjuvant wherein said foam adjuvant is cetostearyl alcohol.

103 . The composition of claim 102 , wherein the foam adjuvant comprises about 0.1% to about 5% by weight of the foamable composition.

104 . The composition of claim 92 , wherein the composition further comprises a penetration enhancer.

105 . The composition of claim 92 , wherein the composition further comprises one or more of propylene glycol, butylene glycols, hexylene glycol, glycerol, pentaerythritol, sorbitol, mannitol, oligosaccharides, dimethyl isosorbide, monooleate of ethoxylated glycerides having about 8 to 10 ethylene oxide units, polyethylene glycol 200-600, transcutol, glycofurol, and cyclodextrins.

106 . The composition of claim 105 , wherein the composition further comprises one or more of propylene glycol, hexylene glycol, glycerol, polyethylene glycol, and dimethyl isosorbide.

107 . The composition of claim 106 , wherein the composition further comprises one or more of propylene glycol, hexylene glycol, glycerol, and dimethyl isosorbide.

108 . The composition of claim 92 , wherein the pH of the foamable composition is between about 4.5 and about 7.0.

109 . The composition of claim 108 , wherein pH of the foamable composition is adjusted using an agent selected from the group consisting of an acid, a base and a buffering agent.

110 . The composition of claim 92 , wherein the organic carrier comprises a PPG alkyl ether.

111 . The composition of claim 110 , wherein the PPG alkyl ether comprises between about 1% and about 20% of the foamable composition.

112 . The composition of claim 108 , wherein the foam is non-flammable, when tested according to European Standard prEN 14851.

113 . The composition of claim 92 , wherein the azelaic acid comprises greater than 10% by weight of the foamable composition.

114 . The composition of claim 113 , wherein the azelaic acid comprises between about 10% and about 25% by weight of the foamable composition.

115 . The composition of claim 114 , wherein the azelaic acid comprises 15% by weight of the foamable composition.

116 . The composition of claim 92 , wherein the polymeric additive comprises a gelling agent.

117 . The composition of claim 116 , wherein the gelling agent is xanthan gum.

118 . The composition of claim 92 , further comprising methylcellulose.

119 . The composition of claim 92 , wherein the at least one surfactant having a hydrophilic lipophilic balance of less than 9 is non-ionic.

120 . The composition of claim 119 , wherein the azelaic acid comprises between about 10% and about 25% by weight of the foamable composition.

121 . A composition comprising:

(a) a foamable composition comprising:

i. 15% by weight of the foamable composition of azelaic acid;

ii. a capric/caprylic triglyceride;

iii. a surface-active agent;

iv. about 0.01% to about 5% by weight of the foamable composition of a gelling agent;

v. a therapeutically active foam adjuvant;

vi. one or more of propylene glycol, butylene glycols, hexylene glycol, glycerol, pentaerythritol, sorbitol, mannitol, oligosaccharides, dimethyl isosorbide, monooleate of ethoxylated glycerides having about 8 to 10 ethylene oxide units, polyethylene glycol 200-600, transcutol, glycofurol, and cyclodextrins;

vii. less than 5% by weight of the foamable composition of short chain alcohols having up to 5 carbon atoms; and

viii. water; and

(b) a propellant wherein the propellant comprises a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the composition; and

wherein said foamable composition has a pH of between about 4.5 and about 7.0.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →